anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Thaumatin-like proteins (TLP), existing in various fruits, have allergenic and pro-inflammatory activities. The current research attempts to reduce the pro-inflammatory activity of litchi TLP (LcTLP) through high hydrostatic pressure (HHP). This study demonstrated that HHP (250-500 MPa, 5-10 min) was a potential technique to reduce the pro-inflammatory activity of LcTLP, which was attributed to the irreversible destruction of the active domain, ie., V-cleft. SDS-PAGE showed no change in the protein profile. Continuous HHP treatment promoted LcTLP unfolding and then reassembling (400 MPa was the transition pressure), and the content of β-sheets decreased from 35.4% to 31.1%. HHP treatment could mitigate inflammatory responses of LcTLP, as confirmed by ELISA and western blot. Molecular dynamics simulations showed significant changes in the residue network under HHP, thereby affecting the V-cleft. These findings provide a theoretical explanation and structural insights into the HHP-induced reduction of pro-inflammatory activity of LcTLP.
Immunoproteasomes are involved in various inflammatory diseases. Upon stimulation, standard constitutive proteasomes are partially replaced by newly formed immunoproteasomes that promote inflammatory responses. How the upregulated immunoproteasomes are cleared to constrain hyper-inflammation is unknown. Recently, our studies showed that the pan-FGFR inhibitor LY2874455 efficiently activates macroautophagy/autophagy in macrophages, leading to the degradation of the immunoproteasomes. Immunoproteasome subunits are ubiquitinated and recognized by the selective autophagy receptor SQSTM1/p62. LY2874455 suppresses inflammation induced by lipopolysaccharide both in vivo and in vitro through autophagic degradation of the immunoproteasomes. In summary, our work uncovers a mechanism of inflammation suppression by autophagy in macrophages.
Metabolic syndrome (MetS) is a combination of metabolic disorders that concurrently act as factors promoting systemic pathologies such as atherosclerosis or diabetes mellitus. It is now believed to encompass six main interacting conditions: visceral fat, imbalance of lipids (dyslipidemia), hypertension, insulin resistance (with or without impairing both glucose tolerance and fasting blood sugar), and inflammation. In the last 10 years, there has been a progressive interest through scientific research investigations conducted in the field of metabolomics, confirming a trend to evaluate the role of the metabolome, particularly the intestinal one. The intestinal microbiota (IM) is crucial due to the diversity of microorganisms and their abundance. Consequently, IM dysbiosis and its derivate toxic metabolites have been correlated with MetS. By intervening in these two factors (dysbiosis and consequently the metabolome), we can potentially prevent or slow down the clinical effects of the MetS process. This, in turn, may mitigate dysregulations of intestinal microbiota axes, such as the lung axis, thereby potentially alleviating the negative impact on respiratory pathology, such as the chronic obstructive pulmonary disease. However, the biomolecular mechanisms through which the IM influences the host's metabolism via a dysbiosis metabolome in both normal and pathological conditions are still unclear. In this study, we seek to provide a description of the knowledge to date of the IM and its metabolome and the factors that influence it. Furthermore, we analyze the interactions between the functions of the IM and the pathophysiology of major metabolic diseases via local and systemic metabolome's relate endotoxemia.
Systems and methods for displaying metrics related to a user are described. Data indicative of glucose levels of the user is received. A first alert point for a potential glucose episode in a data set of time correlated glucose data, e.g., a glucose vs. time curve, is identified if the last received glucose data point satisfies at least one alert condition. A first potential local minimum in a first time period is identified. The first potential local minimum is confirmed as a first start point of a first glucose episode if the first potential local minimum satisfies at least one local minimum condition. An integrated area under the curve over time of a first portion of the graph beginning at the first start point of the first glucose episode to the first alert point is calculated. A first count value is assigned to the first portion.
PURPOSE:To provide the titled drug preparation effective for the remedy of thrombotic diseases, etc. by using dried urokinase as a main component, and compounding the component with a stabilizer composed of an inorganic salt and/ or an organic acid salt and albumin. CONSTITUTION:The objective dried urokinase preparation is obtained by using dried urokinase as a main component, and compounding a stabilizer containing 30-50mg of albumin and 10-20mg of an inorganic salt and/or organic acid salt per 100,000-30,000 IU of urokinase. The combined use of the components results in the synergistic stabilization of the dried urokinase. Since the stabilizer is effective also for the prevention of the decomposition of urokinase by freeze-drying, it is preferable to add the stabilizer prior to the freeze-drying of urokinase. The albumin is preferably those derived from human, and its purity is preferably >=80% determined by electrophoresis.
Two recent open label clinical trials have reported that the anticonvulsant, gamma vinyl-GABA (GVG; vigabatrin), decreases relapse to cocaine use (Brodie et al., 2003, 2005). Vigabatrin increases neural GABA levels by irreversibly inhibiting the primary GABA degradation enzyme, GABA-transaminase; the hypothesized mechanism by which vigabatrin decreases cocaine relapse is by increasing GABA levels, thereby decreasing the effects of cocaine and cocaine-associated environmental cues on extracellular dopamine concentrations in the mesolimbic dopaminergic pathway (Morgan and Dewey, 1998). We are proposing to use our model of repeated dose cocaine self-administration to assess the interaction between vigabatrin and smoked cocaine under controlled laboratory conditions. This 57-day outpatient/inpatient /outpatient/inpatient protocol will evaluate the effects of vigabatrin maintenance (0, 3 g/day) on cocaine craving, subjective effects, and self-administration using a within-subjects design. Non-treatment seeking cocaine-dependent volunteers will be maintained outpatient for 14 days of vigabatrin maintenance prior to beginning each inpatient study phase. During the inpatient phases, volunteers will live on a hospital clinical research unit and will participate in laboratory sessions in which they will have the opportunity to purchase doses of smoked cocaine (0, 12, 25, 50 mg; $5/administration). In addition to measuring cocaine self-administration, we will measure the cardiovascular and subjective effects of repeated cocaine administration and cocaine craving under each vigabatrin maintenance condition. Determining vigabatrin's effects on a range of smoked cocaine doses will provide essential data on the mechanism of the vigabatrin-cocaine interaction.
In this arm an endotracheal tube of size 8 will be used. This is one size smaller than is routine when HFJV is being used for liver tumour ablation procedures in our department. Worth to note is that an endotracheal tube of size 8 is routine in all other surgical procedures, in men, during general anaesthesia.
Trigeminal nerve stimulation will occur by placement of electrodes (1.25" silver electrodes Bio-Flex BF4, Biotens/Vermed, Buffalo, New York, USA) bilaterally on the V1 branches of the trigeminal nerve (CNV) located on the forehead. Current will be generated from the EMS 7500 stimulator (TENS Products, Inc., Granby, CO) (Class II medical device) and will be set to a level that is clearly perceptible by each patient (i.e. tingling sensation) but not uncomfortable or painful. Current level will be determined for each patient at baseline and will likely be between 4-6 milliampere (mA). Active stimulation will occur at 120 Hz with a 250 μs pulse width and with a duty cycle of 30 seconds on to 30 seconds off.
PURPOSE: To obtain a food with addition of an archorrhea preventing agent so as to prevent archorrhea of a liquid polysiloxane compounded as a substitute for a fat component in a food compsn. CONSTITUTION: The food compsn. is a low-calorie food compsn. containing a nonfat component and a fat component. In the whole fat component, about 0.1 to 100wt.% is replaced by a fat substitute. The fat component contains the following components (a) and (b). (a) An edible nonabsorptive indigestible liquid siloxane polymer expressed by general formula (CH3 )3 SiO[(CH3 )2 SiO]b Si(CH3 )3 , wherein (b) is a number with the average from 25 to 500. (b) An enough amt. of an archorrhea preventing agent to prevent leaking of the liquid (a) through an anal sphincter. The archorrhea preventing agent is selected, for example, from fatty acids having about >=37 deg.C melting point or edible digestive source material of these fatty acids, granular silica, and edible nondecomposing water-insoluble fibers from vegetables.
Speech communication depends on accurate perception and identification of speech sounds, which vary across talkers and word or sentence contexts. The ability to map this variable input onto discrete speech sound representations relies on categorization. Recent research and theoretical models implicate the procedural learning system in the ability to learn novel speech and non-speech categories. This connection is particularly intriguing because several language disorders that demonstrate linguistic impairments are proposed to stem from procedural learning and memory dysfunction. One such disorder, Developmental Language Disorder (DLD), affects 7.5% of children and persists into adulthood. While DLD is associated with general linguistic impairments, it is not yet clear how fundamental perceptual and cognitive processes supporting language are impacted, such as the ability to learn novel auditory categories. We examined auditory category learning in children with DLD and typically developed (TD) children using two well-matched nonspeech auditory category learning challenges to draw upon presumed procedural (information-integration) versus declarative (rule-based) learning systems. We observed impaired information-integration category learning and intact rule-based category learning in the DLD group. Quantitative model-based analyses revealed reduced use of, and slower shifting to, optimal procedural-based strategies in DLD and slower shifting to but similarly efficient use of optimal hypothesis-testing strategies. The dissociation is consistent with the Procedural Deficit Hypothesis of language disorders and supports the theoretical distinction of multiple category learning systems. These findings demonstrate that highly controlled experimental tasks assessing perceptual and cognitive abilities can relate to real-world challenges facing individuals with DLD in forming stable linguistic representations.
Stereotactic Body Radiation Therapy (SBRT) followed by pembrolizumab treatment within 7 days of completion. SBRT: 3 x 8 Gy, given 1-2 weeks prior to start of pembrolizumab. Dose of pembrolizumab is 200 mg, every 3 weeks. Patients can continue the pembrolizumab treatment for maximal 2 years.
Provided is a method of creating a record in a reference table contained in a database associated with a medical system. The method includes obtaining a new record barcode which includes pharmaceutical information embedded therein. The pharmaceutical information may include a pharmaceutical identifier and at least one of a pharmaceutical concentration, a pharmaceutical volume, a pharmaceutical expiration date, and a pharmaceutical lot and batch number. The method further includes scanning the new record barcode using a barcode reader associated with the medical system. Upon scanning the new record barcode, a processor associated with the database creates a reference table record in the reference table and populates the reference table record with the pharmaceutical information. Also provided is a system for implementing the above-described method.
PURPOSE:To obtain an anti-inflammatory agent effective for suppressing inflammations, having low toxicity, containing an extract of fruit body or cell of Heterobasidiae as an active ingredient. CONSTITUTION:An anti-inflammatory agent containing an extracted component of fruit body or cell of Heterobasidiae (e.g. Auricularia auricula-judae, A. polytricha, A. mesenterica, etc.) as an active ingredient. The active ingredients of the extracted components are mainly all polysaccharides. The polysaccharides are xylose, mannose, glucuronic acid, etc., in the case of Auricularia auricula- judae. The extracted components are purified by an ordinary purification of protein removal or may be directly used. The extracted components of Auricularia auricula-judae are blended with various drug bases in liquid state, creamy state, etc., and used as an anti-inflammatory drug. The blending ratio of the extracted components used is preferably 0.001-20.0wt.% based on a base such as drug base, cosmetic base, etc., when the lyophilized extracted components are used.
Targeted dynamic balance training. Dynamic balance training will consist of progressive exercise training over three phases, with exercises emphasising dynamic balance control, muscle strength and proprioception. Exercises will be performed four times per week for ten weeks. Exercises will be taught and supervised by a trained kinesiologist. Difficulty of exercises will be increased progressively over time by increasing resistance, time of timed exercises, and distance of walking exercises. Exercises will be progressed to different exercises in each new phase (total 3 phases). Participants will complete six treatment sessions at the university (during weeks 1, 2, 3, 5, 7, and 9) that will be included in the total number of sessions per week. All other sessions will be performed at home.
<P>PROBLEM TO BE SOLVED: To provide a therapeutic antiviral preparation having improved pharmacological characteristics, a dosing regimen for a new antiviral compound not more troublesome than the conventional regimen, or an assay method determining the presence or absence of, or the amount of virus-inhibition.  <P>SOLUTION: The invention relates not only to a phosphorus-substituted compound having antiviral activity, a composition containing such compound and a therapeutic method including a process for dosing such compound, but also to a useful process and an intermediate for preparing such compound. The invention provides new phosphonate-containing analogues of the antiviral compounds. These analogues have all of usefulness of these parent compounds, and provide accumulation of them in cells described below, at need. The compounds of the invention can inhibit RNA-dependent RNA polymerase of retro virus or reverse transcriptase, and therefore, can inhibit duplication of virus.  <P>COPYRIGHT: (C)2007,JPO&INPIT
The principal signs and symptoms of overdose with furosemide are dehydration, blood volume reduction, hypotension, electrolyte imbalance, hypokalemia and hypochloremic alkalosis, and are extensions of its diuretic action.

The acute toxicity of furosemide has been determined in mice, rats and dogs. In all three,the oral LDso exceeded 1,000 mg/kg body weight, while the intravenous LDso ranged from 300 to 680 mg/kg. The acute intragastric toxicity in neonatal rats is 7 to 10 times that of adult rats.

The concentration of furosemide in biological fluids associated with toxicity or death is not known.

Treatment of overdosage is supportive and consists of replacement of excessive fluid and electrolyte losses. Serum electrolytes,carbon dioxide level and blood pressure should be determined frequently. Adequate drainage must be assured in patients with urinary bladder outlet obstruction (such as prostatic hypertrophy).

Hemodialysis does not accelerate furosemide elimination.
PURPOSE: A composition containing jujube or grape fermentation liquid is provided to enhance antioxidation, anti-inflammation, whitening, and anti-wrinkling. CONSTITUTION: A cosmetic composition with anitoxidation and anti-wrinkling effects contains jujube or grape fermentation liquid as an active ingredient. The fermentation liquid is prepared by alcohol fermentation, acetic acid fermentation, or combination thereof. The alcohol fermentation comprises: a step of inoculating activated lactic acid bacteria to jujube or grape juice of 10-30 brix; a step of culturing the juice at 15-50 Deg. for 1-2 week; and a step of fermenting to prepare alcohol fermentation liquid with 1-20% alcohol degrees and 1-20 brix. The cosmetic composition is manufactured in the form of a lotion, skin, nutrition lotion, nutrition cream, massage, essence, and pack.
Dosage forms comprise beta blockers. The beta blockers containing pharmaceutical formulations are liquid aerosols, which are suitable for mucous membrane application. The pharmaceutical formulations do not contain components for delayed release and are administered by devices which release in volume controlled dosages as spray. ACTIVITY : Neuroprotective; Tranquilizer; Antidepressant; Analgesic; Auditory; Hypotensive; Antianginal; Anticonvulsant; Cardiant; Vasotropic; Antiarrhythmic; Hypnotic; Uropathic; Gastrointestinal-Gen; Endocrine-Gen; Antithyroid. No biological data given. MECHANISM OF ACTION : Beta-adrenergic antagonist.
A disposable wiping article is disclosed having at least a first layer and a second plastic film layer. The first layer has a wet extensibility greater than that of the second, layer. The first layer can be a dry creped web of cellulosic fibers, and the second layer can be an apertured, three dimensional plastic film. Selected portions of the first layer are bonded to the second layer to inhibit wet extension of the first layer in the plane of the first layer. In one embodiment, the wiping article comprises a third layer which can be a dry creped, apertured web of cellulosic fibers having a wet extensibility greater than that of the second layer. The second plastic film layer is disposed between the first layer and the third layer and inhibits wet extension of both the first and third layer when wetted.
Described are general means and methods of diagnosing and treating the phenotypic spectrum as well as the overlapping clinical characteristics with several forms of inherited abnormal expression and/or function of the CYP3A4, CYP3A7 and hPXR genes. In particular, polynucleotides of molecular variant CYP3A4, CYP3A7 and hPXR genes which, for example, are associated with insufficient metabolization and/or sensitivety of drugs, and vectors comprising such polynucleotides are provided. Furthermore, host cells comprising such polynucleotides or vectors and their use for the production of variant CYP3A4, CYP3A7 and hPXR proteins are described. In addition, variant CYP3A4, CYP3A7 and hPXR proteins and antibodies specifically recognizing such proteins as well as transgenic non-human animals comprising the above-described polynucleotide or vectors are provided. Described are also methods for identifying and obtaining inhibitors for therapy of disorders related to the malfunction of the CYP3A4, CYP3A7 and hPXR genes as well as methods of diagnosing the status of such disorders. Pharmaceutical and diagnostic compositions comprising the above-described polynucleotides, vectors, proteins, antibodies and inhibitors by the above-described method are provided. Said compositions are particularly useful for diagnosing and treating various diseases with drugs that are substrates, inhibitors or modulators of the CYP3A4, CYP3A7 or hPXR gene product.
This research was planned to determine the effect of breastfeeding on newborns' behavioral pain and comfort scores during heel blood collection. A pretest/posttest experimental-control group design was used. The research was conducted between August 2021 and June 2022. A total of 50 newborns, including 25 in each of the experimental and control groups, were included in the study. An Infant Descriptive Information Form, the COMFORTneo Behaviour Scale, the NIPS-Neonatal Infant Pain Scale, and the LATCH Breastfeeding Diagnosis and Assessment Tool were used in the study. The comfort behaviors and pain scores of infants in the experimental and control groups were evaluated during the heel blood collection process. The comparison of the comfort behaviors (comfort, pain, and distress), differences between pretest-posttest scores on the NIPPS pain score, and crying duration of the newborns in the experimental and control groups indicated a significant difference (p 0.05). The intra-group differences between the mean pretest and posttest scores of both the intervention and control groups were found to be statistically significant (p 0.05). Breastfeeding is an important nursing intervention for reducing procedural pain in newborns. The breastfeeding method reduces pain and distress and increases comfort for newborns during the heel blood collection process.
The purpose of this project is two-fold: 1.) to establish the psychometric properties of the Nursing Home Vision-Specific Health-Related Quality of Life (HRQOL) instrument, and; 2.) to evaluate the responsiveness of this instrument. Responsiveness will be assessed in two independent preliminary prospective intervention evaluations. The first responsiveness evaluation will involve a new spectacle intervention and the second will involve first eye cataract surgery. In addition, we will examine the association between the responsiveness of this instrument, and changes in visual functioning measures and other demographic variables.